<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043805</url>
  </required_header>
  <id_info>
    <org_study_id>2-108-05-085</org_study_id>
    <nct_id>NCT05043805</nct_id>
  </id_info>
  <brief_title>Dextromethorphan Added on for Children With Chronic Irritability</brief_title>
  <official_title>The Study of Risk Factors and Intervention for Children With Chronic Irritability - a Preliminary Approach With Epidemiological, Neuropsychological and Neuroinflammation Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tri-Service General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dextromethorphan Added on for Children With Chronic Irritability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      It is known that the etiology and mechanism of neuropsychiatric diseases may be related to&#xD;
      nerve inflammation. It has been found that dextromethorphan (DM) is an active ingredient in&#xD;
      cough-remedies, which can protect neurons in glial cell cultures in the rat brain from&#xD;
      inflammatory substances. Although the mechanism of DM is still unknown, it may be related to&#xD;
      the regulation of immune dysfunction. Therefore the purpose of this present study was to&#xD;
      investigate the adjuvant treatment with DM in the children and adolescents with chronic&#xD;
      irritability.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This randomized double-blind clinical trial will evaluate 120 outpatients, aged between 7 and&#xD;
      17 years, with chronic irritability. The study subjects will be randomly assigned into one of&#xD;
      the two groups: receiving routine medicine plus DM or routine medicine plus placebo for 8&#xD;
      weeks. Assessments comprising the parents' reported Mood Disorder Questionnaire (MDQ),&#xD;
      Affective Reactivity Index (ARI), the Chinese version of the Child Behavior Checklist&#xD;
      (CBCL-C) scale, the Swanson, Nolan and Pelham Questionnaire (SNAP-IV), the Sleep Disturbance&#xD;
      Scale for Children (SDSC), Problematic smartphone use (PSU) and Checklist for Autism Spectrum&#xD;
      Disorder-Chinese Version (CASD-C). Comparison will be done between groups at baseline and at&#xD;
      8 weeks before-and-after the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritability severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators will measure if the severity improve after using regrow by the ARI scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators will measure if the severity improve after using regrow with regular drug by the SNAP-IV scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Irritable Mood</condition>
  <arm_group>
    <arm_group_label>Dextromethorphan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>add on therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>add on therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>add on therapy</description>
    <arm_group_label>Dextromethorphan</arm_group_label>
    <other_name>regrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>add on therapy</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 7 to 17 who have irritability symptoms will be recruited. They will be&#xD;
             screened for the irritability symptoms with ARI scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not willing to participate in the study after detailed explanation.&#xD;
&#xD;
          -  Patients who could not follow the investigator's instructions.&#xD;
&#xD;
          -  Patients who have problems to express questions or emotional problems exactly.&#xD;
&#xD;
          -  Patients who have severe neurological or mental illness like epileptic disorder,&#xD;
             history of stroke, schizophrenia, bipolar disorder, mental retardation or uncontrolled&#xD;
             suicide risk.&#xD;
&#xD;
          -  Patients who have severe medical illness or surgical conditions like uncontrolled&#xD;
             abnormal thyroid function, history of heart attack, uncontrolled hypertension.&#xD;
&#xD;
          -  Patients who are allergic to methylphenidate or dextromethorphan.&#xD;
&#xD;
          -  Patients with autoimmune disorders&#xD;
&#xD;
          -  Patients with asthma or severe infection disorder currently or in the previous two&#xD;
             months to avoid the influence of the level of cytokines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chin-Bin Yeh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chin-Bin Yeh, M.D., Ph.D.</last_name>
    <phone>+886-919376404</phone>
    <email>chinbinyeh@gmail.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tri-Service General Hospital</investigator_affiliation>
    <investigator_full_name>Chin-Bin Yeh, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

